Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals | Small Cap
Health Score : 4.70Vineet Laboratories Ltd, operating in the Pharmaceuticals & Biotechnology sector, demonstrates a mixed financial performance. The company shows notable strength in solvency and growth, indicating a stable capital structure and significant expansion in key areas like revenue and assets. However, it faces challenges in profitability, efficiency, and coverage, which could impact its long-term sustainability. While the company has managed to grow its assets and revenue substantially, its profitability margins remain thin. The company's ability to service its debt is also a concern. These factors suggest a need for strategic adjustments to enhance overall financial health and competitive positioning. The company's heavy reliance on debt financing and low-profit margins highlight potential vulnerabilities. Continued focus on operational improvements and strategic investments is crucial for sustainable growth and value creation.
Health Score : 4.70Vineet Laboratories Ltd, operating in the Pharmaceuticals & Biotechnology sector, demonstrates a mixed financial performance. The company shows notable strength in solvency and growth, indicating a stable capital structure and significant expansion in key areas like revenue and assets. However, it faces challenges in profitability, efficiency, and coverage, which could impact its long-term sustainability. While the company has managed to grow its assets and revenue substantially, its profitability margins remain thin. The company's ability to service its debt is also a concern. These factors suggest a need for strategic adjustments to enhance overall financial health and competitive positioning. The company's heavy reliance on debt financing and low-profit margins highlight potential vulnerabilities. Continued focus on operational improvements and strategic investments is crucial for sustainable growth and value creation.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
-1.75
Industry Median
19.41
Small Cap Median
18.08
P/E RATIO
-1.45
P/B RATIO
2.06
Industry Median
1.98
Small Cap Median
2.03
P/S RATIO
0.39
Industry Median
2.06
Small Cap Median
1.64
Others
PEG RATIO
0.00
EV/EBITDA RATIO
-2.32
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹31.7 as on Feb 20, 2026.
Growth Score : 7.00The company's growth shows a varied performance. Revenue has grown substantially. Asset growth is also strong, suggesting significant investments and expansion. However, earnings per share growth is low, indicating that profitability has not kept pace with revenue and asset growth. While the company is expanding, measures to improve profitability and efficiency are necessary to translate growth into enhanced shareholder value.
Revenue Growth RateExcellentOperating Profit Growth RateExcellent
Earnings Per Share (EPS) GrowthPoorAsset Growth RateExcellentNet Income Growth RateAverage| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | -21.51 | 11.09 | -29.06 | -50.2 | -20.8 |
| Operating Profit Growth Rate | 61.47 | -41.79 | -6.01 | -326.11 | 152.15 |
| Earnings Per Share (EPS) Growth | 272.04 | -81.21 | -16.92 | -2048.15 | 105.51 |
| Asset Growth Rate | 22.6 | -13.1 | 0.88 | -19.11 | 31.99 |
| Net Income Growth Rate | 273.03 | -81.17 | -17.6 | -2060.19 | 105.5 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Vineet Laboratories Ltd | 4.70 | -1.45 | Neutral | 8.49 | -5.28 | 1.11 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Vineet Laboratories Ltd is an Indian pharmaceutical company specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. Leveraging complex chemistry and multi-step synthesis, the company caters to various therapeutic areas. With a focus on custom synthesis and contract manufacturing, it holds a niche position in the specialized pharma chemical market.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Vineet Laboratories Ltd's P/E ratio (TTM) is -1.75, compared to the industry median of 19.41 and large cap median of 18.08.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Vineet Laboratories Ltd's P/B ratio is 2.06, compared to the industry median of 1.98 and large cap median of 2.03.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Vineet Laboratories Ltd's P/S ratio is 0.39, compared to the industry median of 2.06 and large cap median of 1.64.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Vineet Laboratories Ltd's PEG ratio is 1.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Vineet Laboratories Ltd's EV/EBITDA ratio is -2.32.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Vineet Laboratories Ltd's ROE is 2.43%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Vineet Laboratories Ltd's ROA is 6.80%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Vineet Laboratories Ltd's ROCE is 8.49%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Vineet Laboratories Ltd's operating margin is 14.29%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Vineet Laboratories Ltd's net margin is 1.87%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Vineet Laboratories Ltd's current ratio is 1.46.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Vineet Laboratories Ltd's debt-to-equity ratio is 0.22.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Vineet Laboratories Ltd's interest coverage ratio is 1.26.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Vineet Laboratories Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Vineet Laboratories Ltd's EPS is 105.51.
(Source line: "Ratios as of 22 Oct 2026, based on last traded price of ₹31.70. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 2007 (as Vineet Laboratories Private Limited)
Headquarters: Hyderabad, Telangana
Core Offerings: Active Pharmaceutical Ingredients (APIs), Advanced Pharmaceutical Intermediates, Specialty Chemicals, Custom Synthesis & Contract Manufacturing
Stock Listing: NSE (VINEETLAB), BSE (543298)
Promoter: Mr. Vineet Kumar
Vineet Laboratories was incorporated in July 2007 as a private limited company. It commenced manufacturing operations in 2008, focusing on intermediates. Over the years, the company expanded its product portfolio to include APIs and advanced intermediates, investing in R&D and manufacturing capabilities. In October 2023, the company successfully launched its Initial Public Offering (IPO) on the NSE SME platform, transitioning to a public limited company in June 2023.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceutical Products (APIs and Intermediates) | 100% | N/A (single segment) |
Active Pharmaceutical Ingredients (APIs) & Intermediates: Manufactures a range of APIs and advanced intermediates used in various therapeutic segments like anti-hypertensive, anti-fungal, and anti-psychotic drugs.
Complex Chemistry: Specializes in multi-step synthesis and handling complex chemical reactions to produce high-value pharmaceutical components.
Custom Synthesis & Contract Manufacturing: Offers tailored development and manufacturing services for clients, catering to specific chemical synthesis requirements.
Mr. Vineet Kumar - Chairman & Managing Director. He is the founder of the company and brings over two decades of extensive experience in the pharmaceutical manufacturing industry, guiding the company's strategic vision and operational excellence.
No major subsidiaries reported.
Initial Public Offering (IPO) on NSE SME platform in October 2023. No major recent corporate actions on record apart from the IPO.
The Vineet Laboratories Ltd share price today is ₹31.70 on NSE (VINEETLAB), as of 24 Oct 2026.
As of 22 Oct 2026, Vineet Laboratories Ltd share price is ₹31.70, with previous close ₹31.70. Today's range is ₹31.70 to ₹31.70. The 52-week range is ₹27.96 to ₹43.50.
As of today, Vineet Laboratories Ltd's market cap is ₹29.16 crore (Small Cap).
Vineet Laboratories Ltd's current P/E ratio is -1.75, compared to the Pharmaceuticals & Biotechnology sector average of 35.
Vineet Laboratories Ltd's current P/B ratio is 2.06.
Vineet Laboratories Ltd's current dividend yield is N/A. Last dividend of ₹0.50 per share was declared on 20-May-2024 (recommended).
Vineet Laboratories Ltd's EPS (TTM) is ₹105.51.
Vineet Laboratories Ltd is an Indian pharmaceutical company specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. Leveraging complex chemistry and multi-step synthesis, the company caters to various therapeutic areas. With a focus on custom synthesis and contract manufacturing, it holds a niche position in the specialized pharma chemical market.
Vineet Laboratories Ltd is promoted by Mr. Vineet Kumar, holding 5.98% as of 22 Oct 2026.
Vineet Laboratories Ltd is listed on NSE (VINEETLAB) and BSE (543298). Its next quarterly results are expected on August 2024 (expected).
Cash Earnings Per Share (Cash EPS)
